Hepatitis C virus (HCV) remains a major medical problem. Antiviral treatment is only partially effective and a vaccine does not exist. Development of more effective therapies has been hampered by the lack of a suitable small animal model. Although xenotransplantation of immunodeficient mice with human hepatocytes has shown promise, these models are subject to important challenges. Building on the previous observation that CD81 and occludin comprise the minimal human factors required to render mouse cells permissive to HCV entry in vitro 4 , we attempted murine humanization via a genetic approach. Here we show that expression of two human genes is sufficient to allow HCV infection of fully immunocompetent inbred mice. We establish a precedent for applying mouse genetics to dissect viral entry and validate the role of scavenger receptor type B class I for HCV uptake. We demonstrate that HCV can be blocked by passive immunization, as well as showing that a recombinant vaccinia virus vector induces humoral immunity and confers partial protection against heterologous challenge. This system recapitulates a portion of the HCV life cycle in an immunocompetent rodent for the first time, opening opportunities for studying viral pathogenesis and immunity and comprising an effective platform for testing HCV entry inhibitors in vivo.
Hepatitis C virus (HCV) remains a major medical problem. Antiviral treatment is only partially effective and a vaccine does not exist. Development of more effective therapies has been hampered by the lack of a suitable small animal model. Although xenotransplantation of immunodeficient mice with human hepatocytes has shown promise, these models are subject to important challenges. Building on the previous observation that CD81 and occludin comprise the minimal human factors required to render mouse cells permissive to HCV entry in vitro 4 , we attempted murine humanization via a genetic approach. Here we show that expression of two human genes is sufficient to allow HCV infection of fully immunocompetent inbred mice. We establish a precedent for applying mouse genetics to dissect viral entry and validate the role of scavenger receptor type B class I for HCV uptake. We demonstrate that HCV can be blocked by passive immunization, as well as showing that a recombinant vaccinia virus vector induces humoral immunity and confers partial protection against heterologous challenge. This system recapitulates a portion of the HCV life cycle in an immunocompetent rodent for the first time, opening opportunities for studying viral pathogenesis and immunity and comprising an effective platform for testing HCV entry inhibitors in vivo.
Humans and chimpanzees are the only species permissive to HCV infection. The basis for this highly restricted tropism is not completely understood, but may result from viral dependence on host factors present in only a few cell types. Murine cells are resistant to HCV entry, show inefficient viral replication, and may be blocked at later life cycle steps. HCV enters hepatocytes through the combined action of at least four host molecules: CD81 (ref. 1), scavenger receptor type B class I (SCARB1) 2 , claudin 1 (CLDN1) 3 and occludin (OCLN) 4 . We have previously shown that CD81 and OCLN comprise the minimal human factors required for HCV uptake by rodent cells 4 . This led to the hypothesis that expression of these human orthologues could render mice susceptible to HCV infection in vivo. We therefore constructed recombinant adenoviruses encoding human CD81, SCARB1, CLDN1 and/or OCLN. Intravenous delivery of these vectors resulted in 100 to 1,000-fold overexpression of the corresponding messenger RNA in the murine liver and strong expression of all four proteins with the expected subcellular distribution ( Supplementary Fig. 1 ). We determined that 18-25% of murine hepatocytes expressed human CD81 and OCLN together, and approximately 5% of cells expressed all four heterologous genes ( Supplementary Fig. 2b-d) . These results encouraged us to investigate infection of these animals. Unfortunately, HCV replication in mouse cells is inefficient in vitro and in vivo [5] [6] [7] [8] [9] . Consistent with this, challenge of mice expressing all four human factors with a firefly luciferase (Fluc)-encoding HCV genome (Jc1FLAG2(p7Fluc2A)) did not yield bioluminescent signal above background ( Supplementary Fig. 3a ). Direct measurement of Jc1FLAG2(p7Fluc2A) genome levels by polymerase chain reaction with quantitative reverse transcription (qRT-PCR) demonstrated a slight increase in HCV RNA in the serum (at 3 h) and liver (at 3 and 24 h); at 72 h, however, the signal was reduced to background ( Supplementary Fig. 3b-d) . These data highlight the difficulty of detecting HCV infection in cell types that do not support robust replication. In mouse cells, this defect may result from incompatibility between the viral replication machinery and murine factors and/or from exacerbated murine innate antiviral responses. Furthermore, adenoviral gene delivery strongly induces interferonstimulated mouse genes, including viperin (also known as Rsad2), Ifi44, Mx1, Oas1, Cxcl10 and Eif2ak2 (also known as PKR), creating an environment that mimics recombinant IFN-a treatment ( Supplementary  Fig. 4 ) and may antagonize HCV replication 10 .
As an alternative approach, we constructed a bicistronic HCV genome expressing CRE recombinase (Bi-nlsCre-Jc1FLAG2, abbreviated HCV-CRE), which activates a loxP-flanked luciferase reporter in the genome of the Gt(ROSA)26Sor tm1(Luc)Kaelin (Rosa26-Fluc) mouse 11 . Hydrodynamic delivery of HCV-CRE RNA into Rosa26-Fluc mice led to reporter signal in the liver, indicating that CRE recombinase is active in the context of the HCV genome ( Supplementary Fig. 5 ). Delivery of a polymerase-defective HCV-CRE RNA produced similar results, indicating that significant CRE production was derived from initial translation without the need for replication ( Supplementary Fig.  5 ). To test whether mice could be infected by authentic HCV particles, we generated Rosa26-Fluc animals expressing human CD81 and OCLN, or all four human entry factors, and inoculated these mice with cell-culture-derived HCV-CRE. In mice expressing all four transgenes, luciferase signals increased longitudinally, peaked at approximately 72 h after infection, and decreased thereafter; mice lacking the transgenes did not show significant reporter activity ( Fig. 1b and Supplementary Fig. 6 ). All mice expressing at least human CD81 and OCLN could be successfully infected. Loss of signal after 72 h was probably due to strong antivector immunity, as evidenced by the increased frequencies of natural killer (NK) cells ( Supplementary  Fig. 7a ); depletion of NK cells before adenovirus injection prolonged luminescence activity ( Supplementary Fig. 7c ). Bioluminescent signals were dependent on the doses of both adenovirus and HCV-CRE ( Supplementary Fig. 6 ). HCV core, NS3 or NS5A could not be detected (data not shown), probably owing to inefficient viral replication in murine hepatocytes. To estimate the number of HCV-infected liver cells, we therefore used an indicator mouse strain in which CRE leads to activation of a nuclear-localized green fluorescent protein/b-galactosidase (GNZ) reporter (B6.129-Gt(ROSA)26Sor tm1Joe /J, abbreviated Rosa26-GNZ) 12 . We observed HCV-CRE infection in approximately 4-5% of murine hepatocytes expressing human CD81 and OCLN ( Fig. 1c and Supplementary Fig. 2h ) and up to 20% expressing all four factors ( Fig. 1c ). We did not observe HCV uptake in non-parenchymal liver cells. These frequencies are consistent with previous estimates from primary human hepatocyte cultures 13, 14 and HCV-positive patient tissues 15 , although our system represents a single cycle infection and does not fully reflect the natural equilibrium. Taken together, these data provide-to our knowledge for the first time-evidence that mice can be rendered susceptible to HCV infection by a defined set of human genes.
Previous studies in Chinese hamster ovary (CHO) and mouse fibroblast (NIH3T3) cells have shown that CD81 and OCLN are the primary determinants of HCV tropism at the level of entry 4 . To investigate the in vivo determinants of species restriction, we delivered combinations of human or mouse CD81, SCARB1, CLDN1 and OCLN to Rosa26-Fluc mice. In accordance with the in vitro data, HCV permissivity increased 6-10-fold in mice expressing human CD81 and OCLN, compared to those expressing only murine factors. Notably, addition of exogenous human or mouse SCARB1/CLDN1 ( Fig. 1d ) boosted permissivity compared to human CD81/OCLN alone ( Fig. 1b ), indicating that low endogenous entry factor levels may limit infection. Although overexpression of mouse CD81 or OCLN in combination with the other human entry factors permits low-level uptake, human CD81 and OCLN are required for optimal infection. To verify authentic co-receptor function, we delivered entry factors bearing mutations previously shown to disrupt their activities. CD81 mutations F186L and E188K are known to abrogate soluble E2 binding and to reduce HCV uptake by human hepatocytes 16 . Indeed, expression of mutant human CD81 reduced in vivo entry efficiency by about 50% (Fig. 1e) . A human OCLN chimaera in which the second extracellular loop is replaced with the murine sequence has been shown to impair HCV entry in vitro by approximately fourfold 4 . Concordantly, HCV susceptibility of mice expressing the chimaeric molecule was reduced by approximately 50% (Fig. 1e ). These data indicate that infection of murine hepatocytes in vivo is dependent on the native functions of human CD81 and OCLN.
Unlike the human-restricted entry factors, mouse SCARB1 seems to support HCV uptake in vitro 4 and in vivo ( Fig. 1b) . To validate the importance of this endogenous factor, we crossed mice with a disruption in Scarb1 (SCARB1 2/2 ) 17 to the Rosa26-Fluc background. Expression of human CD81, CLDN1 and OCLN in mouse SCARB1 2/2 Rosa26-Fluc mice reduced HCV-CRE infection efficiency by ,90%, as compared to SCARB1 1/1 , and ,50% compared to SCARB1 1/2 mice (Fig. 1f ). This reduction seems to be a direct consequence of murine SCARB1 deficiency, and not transduction efficiency, as expression levels of CD81, CLDN1 and OCLN were similar in wild-type (Supplementary Fig. 1g ) and SCARB1 knockout mice ( Supplementary  Fig. 8 ). Complementing mouse SCARB1 2/2 Rosa26-Fluc mice with human CD81, CLDN1 and OCLN and SCARB1 of either human or mouse origin fully restored infectivity (Fig. 1f ). These data provide the first direct evidence that SCARB1 is a bona fide HCV entry factor in vivo. Taken together, these results indicate that infection of humanized mice occurs via authentic entry pathways, and highlight the value of this system for studying HCV co-receptor biology in vivo.
Despite considerable efforts, the lack of preventative or therapeutic HCV vaccines remains a major clinical challenge. Delivery of antibodies via passive immunization might be particularly suitable to block HCV entry, possibly limiting graft re-infection during liver transplantation and potentially boosting treatment success. Antibodies against E2 and CD81 have been shown to block HCV infection in cell culture 13, 18 and human liver chimaeric mice 19, 20 . We investigated passive immunization in the genetically humanized model. Delivery of anti-CD81 antibodies resulted in a dose-dependent inhibition of HCV-CRE infection, whereas isotype control immunoglobulins had no effect ( Fig. 2a, d) . Similarly, pre-incubation of HCV-CRE with antibodies directed against E2 (clone 3/11), but not an isotype control, significantly inhibited infection ( Fig. 2b, e ). These data further affirm that HCV is taken up in a glycoprotein-specific fashion in vivo and suggest the utility of this model for evaluation of passive immunization strategies.
Induction of broad-spectrum adaptive immunity is a key goal of HCV vaccine research. A promising candidate is a recombinant vaccinia virus (rVV) vector expressing HCV proteins, which has been shown to induce adaptive responses in rodents and chimpanzees 21 . We confirmed that HCV infection in our mouse model was observed across a panel of chimaeras expressing the structural proteins of diverse HCV genotypes ( Fig. 3a) . To evaluate this candidate in genetically humanized animals, Rosa26-Fluc mice were immunized intraperitoneally with 1 3 10 7 plaque forming units (p.f.u.) of rVV expressing the HCV proteins C-E1-E2-p7-NS2 (strain HCV-1, genotype 1a) 22 . Robust titres of anti-E2 antibodies ( Fig. 3b ) and decreased susceptibility to heterologous challenge with HCV-CRE expressing the structural proteins of genotypes 1b, 2a, or 4a ( Fig. 3c ) were observed. Protection directly correlated with the levels of anti-E2 antibodies in the serum. Challenge with genotype 1b (strain Con1) HCV-CRE virus, the envelope proteins of which are closely related to those of HCV-1, resulted in complete protection in two out of ten animals ( Fig. 3d-f ). Pooled sera of immunized-but not non-immune-mice neutralized diverse HCV genotypes in vitro ( Supplementary Fig. 9 ) and reduced infection by 50% when transferred passively (Fig. 2c, f) . These data demonstrate the value of the genetically humanized mouse as the first immunocompetent small animal model amenable to HCV challenge.
This study represents an important step forward in developing a robust small animal model for HCV infection and immunity. To our knowledge, this is the first time that any step in the viral life cycle has been recapitulated in a rodent simply by the expression of human genes. Previously developed liver chimaeric mice are susceptible to 
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HCV infection and support the entire viral life cycle [23] [24] [25] . Despite recent improvements 23 , however, these models are hampered by low throughput, intra-experimental variability, and high costs 26 . Furthermore, the lack of a functional immune system negates their value for vaccination studies. The inbred mouse model presented here is not only susceptible to infection by diverse HCV genotypes, but it is also fully immunocompetent, providing the first small animal platform suitable for combined immunization and challenge studies. Although it may eventually be desirable to transgenically express the HCV entry factors, adenoviral expression allows rapid testing of various mutant proteins on diverse backgrounds. The genetically humanized mouse model provides proof of principle for such applications and holds promise for assessing the immunogenicity and efficacy of HCV vaccines.
METHODS SUMMARY
Mice. Antibodies. Blocking antibodies against CD81 (JS81) and IgG1 control antibodies were obtained from BD Biosciences. Antibodies against NS5A 28 and E2 (clone 3/11) 29 have been described previously. Antibodies for the detection of human CD81 were purchased from BD Biosciences, OCLN from BD Biosciences (for histology) and from Invitrogen (for western blotting), CLDN1 from Invitrogen (for western blotting) and Abcam (for histology), and SCARB1 from Genetex (for histology) and from BD Biosciences (for western blotting). Antibodies for in vivo depletion of T cells (anti-mouse CD4 and anti-mouse CD8) were obtained from Biolegend and the antibody for depletion of NK cells (anti-mouse Asialo GM1) was purchased from Cedarlane. Fluorochrome-conjugated antibodies against mouse CD3, CD4, CD8, CD49b, Ly-6G were obtained from BD Biosciences and the IRDye700-conjugated anti-Luciferase antibody was acquired from Acris antibodies and Bethyl Laboratories. Adenovirus constructs. Adenoviral constructs encoding human and murine homologues of the four HCV entry factors (CD81, SCARB1, CLDN1 and OCLN) and fluorescently tagged human SCARB1, CLDN1 and OCLN were created using the AdEasy Adenoviral Vector System (Agilent Technologies) according to the manufacturer's instructions. Briefly, human and murine entry factor cDNA was PCR-amplified from TRIP-based constructs 4 and inserted into the pShuttle-CMV using KpnI/XhoI sites (KpnI/NotI for human SCARB1). Mouse Kate-SCARB1, Cerulean-CLDN1, and Venus-OCLN fusions were cut from existing TRIP-based constructs and inserted into pShuttle-CMV using compatible restriction sites. Recombinant pShuttle-CMV plasmids were linearized with PmeI and ligated to pAdEasy by homologous recombination followed by electroporation into BJ5183 cells (Agilent). Recombinant pShuttle-pAdEasy constructs were identified by PacI restriction analysis. All plasmid constructs were verified by DNA sequencing. Primer sequences were as follows. Human CD81, forward primer, CGCGGT ACCCCACCATGGGAGTGGAGGGCTGCAC; reverse primer, ACGCTCGAG TCAGTACACGGAGCTGTTCC. Mouse Cd81, forward, GCATACAGGGTAC CGCCACCATGGGAGTGGAGGGCTGCACCAAA; reverse, GCATACAGCT CGAGTCAGTACACGGAGCTGTTCCGGAT. Human SCARB1, forward, CGC GGTACCCCACCATGGGCTGCTCCGCCAAAGC; reverse, CAGCGCTGCG GCCGCCTACAGTTTTGCTTCCTGCA. Mouse Scarb1, forward, GCATACAG GGTACCGCCACCATGGGCGGCAGCTCCAGGGCGCGC; reverse, GCATAC AGCTCGAGCTATAGCTTGGCTTCTTGCAGCAC. Human CLDN1, forward, CGCGGTACCCCACCATGGCCAACGCGGGGCTGCA; reverse, ACGCTCGA GTCACACGTAGTCTTTCCCGC. Mouse Cldn1, forward, GCATACAGGGTA CCGCCACCATGGCCAACGCGGGGCTGCAGCTG; reverse, GCATACAGC TCGAGTCACACATAGTCTTTCCCACTAGA. Human OCLN, forward, CGCG GTACCCCACCATGTCATCCAGGCCTCTTGA; reverse, ACGCTCGAGCTA TGTTTTCTGTCTATCAT. Mouse Ocln, forward, GCATACAGGGTACCGCC ACCATGTCCGTGAGGCCTTTTGAAAGT; reverse, GCATACAGCTCGAGC TAAGGTTTCCGTCTGTCATAATC. Production of recombinant adenoviruses. Adenoviral stocks were generated as previously described 30 . Briefly, adenoviral constructs were transfected into HEK293 cells (American Type Culture Collection) using the calcium-phosphate method. Transfected cultures were maintained until cells exhibited full cytopathic effect (CPE), then harvested and freeze-thawed. Supernatants were serially passaged two more times with harvest at full CPE and freeze thawed. For virus purification, cell pellets were resuspended in 0.01 M sodium phosphate buffer pH 7.2 and lysed in 5% sodium-deoxycholate, followed by DNase I digestion. Lysates were centrifuged and the supernatant was layered onto a 1.2-1.46 g ml 21 CsCl gradient, then spun at 95,389g on a Beckman Optima 100K-Ultra centrifuge using an SW28 spinning-bucket rotor (Beckman-Coulter). Adenovirus bands were isolated and further purified on a second CsCl gradient using an SW41.Ti spinning-bucket rotor. Resulting purified adenoviral bands were isolated using a 18.5G needle and twice-dialysed against 4% sucrose. Adenovirus concentrations were measured at 10 12 times the OD 260 reading on a FLUOstar Omega plate reader (BMG Labtech). Adenovirus stocks were aliquoted and stored at 280 uC. Production of recombinant vaccinia virus. rVV expressing HCV-1 C-NS2 (rVV E12 C/B from Chiron Corporation) was obtained through the National Institutes of Health AIDS Research and Reference Reagent Program 31, 32 . rVV was amplified by infecting HeLa S3 cells in suspension culture at a multiplicity of infection of 0.5 for 48 h. Intracellular virus was released by three freeze-thaw cycles and sonication. The virus was pelleted over a 36% sucrose cushion and resuspended in PBS 33 . HCV genome construction. Jc1FLAG2(p7Fluc2A) is a fully infectious HCV reporter genome similar to Jc1FLAG2(p7nsGluc2A) 34 . This monocistronic genome encodes a Flag epitope, followed by a Gly-Ser-Gly-Ala linker, fused to the N terminus of E2. The Fluc reporter, in tandem with the foot and mouth disease virus autoproteolytic peptide sequence (2A), was inserted between p7 and NS2. Bi-nlsCre-JC1FLAG2 (HCV-CRE) was created by amplification of nlsCre-recombinase from a TRIP-based construct, followed by insertion into the MluI/PmeI sites of a wild-type or polymerase defective (GNN) BiYpet-JC1FLAG2 (ref. 14) genome, replacing Ypet. nlsCre was similarly inserted into bicistronic versions of intergenotypic chimaeras encoding the core-NS2 sequences of Con1 (1b), ED43 (4a), HK6a (6a) and QC69 (7a), which have been previously described 35 . All plasmid constructs were verified by DNA sequencing. Primer sequences for CRE were: forward, CCCAACGCGT ATGCCCAAGAAGAAGAGGAAGGTGTCCA; reverse, AGGGTTTAAACTTA CTTGTACAGATCGCCATCTTC. HCV generation and infections. Huh-7.5.1 or Huh-7.5 cells were electroporated with in vitro transcribed full-length HCV RNA. Seventy-two hours after electroporation, the medium was replaced with DMEM containing 1.5% FBS and supernatants were harvested every six hours starting from 72 h. Pooled supernatants were clarified by centrifugation at 1,500g, filtered through a 0.45 mm bottle top filter (Millipore) and concentrated using a stirred cell (Millipore). Viral titres (TCID 50 ) were determined using Huh-7.5 cells as previously described 28 . E2 antibody ELISAs. To determine end-point titres (EPT) of mouse sera, microplates (Corning Costar 3690) were coated with Galanthus nivalis lectin (GNL; Sigma) at 5 mg ml 21 overnight at 4 uC. Microwells were washed four times with PBS containing 0.05% Tween 20 and blocked with non-fat milk (NFM, 4%; BioRad) diluted in the wash buffer. HCV glycoproteins E1 and E2 were produced by transient transfection of 293T cells with phCMV-H77 and solubilised in lysis buffer (25 mM Tris pH 7.6, 140 mM NaCl, 1% Triton X-100, 0.5% NP-40 & 0.02% sodium azide). To adsorb E1E2, transfected cell lysate was diluted 1:30 in wash buffer containing NFM (1%) and incubated in the microwells for 1.5 h at room temperature (22 uC) . Following blocking and washing, serially diluted mouse sera were added to the ELISA plates and incubated at room temperature for 1 h. Microwells were washed four times and incubated with peroxidase-conjugated goat anti-mouse IgG F(ab9) 2 (diluted 1:2,000) at room temperature for 1 h. Following detection with tetramethylbenzidine substrate (TMB; Pierce), absorbance at 450 nm was measured with a micoplate reader (Molecular Devices). The EPT of each serum was defined as the reciprocal of the dilution giving a threefold higher signal than the negative control. The positive control was a mixture of sera from 12 mice immunized with E2 and diluted at 1:2,000; the negative control was serum from non-immunized Rosa26-Fluc mice. Owing to high non-specific reactivity in mouse sera, only an EPT .200 is considered a true positive signal in this assay. Each ELISA was done in duplicate. Histological detection of HCV entry factors. Liver and spleen of mice injected with adenoviruses encoding human entry factors were harvested 24 h after injection and fixed using 4% paraformaldehyde. Tissue sections (8 mm) were deparaffinized and subjected to antigen retrieval by boiling for 30 min in citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0). Entry factors were stained with human-specific primary antibodies for 16 h at 4 uC followed by secondary antibody staining using Alexa 488 or Alexa 633-conjugated antibodies for 2 h at room temperature. For in situ detection of EGFP fluorescence, mouse tissue was immediately frozen in O.C.T. (Optimal Cutting Temperature) compound at 280 uC. Tissue sections (,5-6 mm) were cut on poly-L-lysine coated slides. Secondary antibodies goat anti-mouse or goat anti-rabbit Alexa 488-or rhodamine conjugates (Invitrogen; 1:1,000) were used for immunofluorescence. Nuclei were detected using DAPI in VectaShield Mounting medium (Vector Laboratories). Images were captured on an Axioplan 2 imaging fluorescence microscope (Zeiss) using Metavue Software (Molecular Devices). Images were processed using ImageJ software (NIH). Isolation of murine hepatocytes. Mice were anaesthetized by intraperitoneal injection of a mixture of 100 mg kg 21 ketamine and 10 mg kg 21 xylazine. Livers were perfused through the inferior vena cava for 5 min each with chelating buffer (0.5 mM EGTA, 0.05 M HEPES pH 7.3 in Ca/Mg-free HBSS) at a flow rate of 2 ml min 21 followed by collagenase solution (4.8 mM CaCl 2 , 100 U ml 21 collagenase type IV,
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